# RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

> **NCT01175343** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 45 (actual)

## Conditions studied

- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Stage IV Fallopian Tube Cancer
- Stage IV Ovarian Cancer
- Stage IV Primary Peritoneal Cancer

## Interventions

- **DRUG:** Gamma-Secretase Inhibitor RO4929097
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT01175343
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2012-10
- **Final completion:** 2015-08
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2017-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01175343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01175343, "RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01175343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*